Clinical Trial

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).
Trial Details
NCT Number NCT06900192
Lead Sponsor Stanford University
Collaborators: Orca Biosystems, Inc.
Conditions Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Enrollment 10 participants
Start Date 2025-03
Primary Completion 2029-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2025-03-28